Preventive treatment with Eloctate (efmoroctocog alfa) for up to five years led to sustained reductions in all bleed types…
Articles by Lindsey Shapiro, PhD
About a quarter (24.4%) of men with hemophilia A and B seen at a clinic in Turkey met…
A small percentage of young people with hemophilia A who are on preventive treatment with Hemlibra (emicizumab) experience…
The approval by the U.S. Food and Drug Administration (FDA) of BioMarin Pharmaceutical’s Roctavian (valoctocogene roxaparvovec-rvox) late last month…
The Hemophilia Federation of America (HFA) is now offering a “clinical trial finder” to help people with hemophilia…
Electrically stimulating the vagus nerve — the main set of nerve fibers that control involuntary bodily functions — significantly reduced…
Weekly treatment with the experimental therapy marstacimab (PF-06741086) was found to significantly reduce bleed rates for adult and adolescent…
Switching to Rebinyn (nonacog beta pegol) from other standard or extended half-life replacement therapies led to “robust” reductions in…
About one-third of moderate-to-severely affected people with hemophilia perceived declines in their daily functional abilities over a period of…
SerpinPC, an investigational treatment that Centessa Pharmaceuticals is developing for hemophilia, will advance to interventional Phase 2 clinical…